Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study

Cardiovasc Diabetol. 2010 May 25:9:21. doi: 10.1186/1475-2840-9-21.

Abstract

Aim: Studies of beta blockade in patients with type 2 diabetes have shown inferiority of metoprolol treatment compared to carvedilol on indices of insulin resistance. The aim of this study was to examine the effect of metoprolol versus carvedilol on endothelial function and insulin-stimulated endothelial function in patients with type 2 diabetes.

Method: 24 patients with type 2 diabetes were randomized to receive either 200 mg metoprolol succinate or 50 mg carvedilol daily. Endothelium-dependent vasodilation was assessed by using venous occlusion plethysmography with increasing doses of intra-arterial infusions of the agonist serotonin. Insulin-stimulated endothelial function was assessed after co-infusion of insulin for sixty minutes. Vaso-reactivity studies were done before and after the two-month treatment period.

Results: Insulin-stimulated endothelial function was deteriorated after treatment with metoprolol, the percentage change in forearm blood-flow was 60.19% +/- 17.89 (at the highest serotonin dosages) before treatment and -33.80% +/- 23.38 after treatment (p = 0.007). Treatment with carvedilol did not change insulin-stimulated endothelial function. Endothelium-dependent vasodilation without insulin was not changed in either of the two treatment groups.

Conclusion: This study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type 2 diabetes.

Trial registration: Current Controlled Trials NCT00497003.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / adverse effects
  • Adrenergic beta-Antagonists / therapeutic use*
  • Carbazoles / adverse effects
  • Carbazoles / therapeutic use*
  • Carvedilol
  • Denmark
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiopathology
  • Female
  • Forearm / blood supply*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Infusions, Intra-Arterial
  • Insulin / therapeutic use*
  • Insulin Resistance
  • Male
  • Metoprolol / adverse effects
  • Metoprolol / therapeutic use*
  • Middle Aged
  • Nitroprusside / administration & dosage
  • Photoplethysmography
  • Propanolamines / adverse effects
  • Propanolamines / therapeutic use*
  • Regional Blood Flow
  • Serotonin / administration & dosage
  • Time Factors
  • Treatment Outcome
  • Vasodilation / drug effects*
  • Vasodilator Agents / administration & dosage

Substances

  • Adrenergic beta-Antagonists
  • Carbazoles
  • Hypoglycemic Agents
  • Insulin
  • Propanolamines
  • Vasodilator Agents
  • Carvedilol
  • Nitroprusside
  • Serotonin
  • Metoprolol

Associated data

  • ClinicalTrials.gov/NCT00497003